Skip to main content
. 2016 Jun 13;113(26):7142–7147. doi: 10.1073/pnas.1600074113

Fig. 5.

Fig. 5.

FKBP65 does not direct LH2 toward procollagen Iα1. Bright-field PLA for LH2 and procollagen-Iα1 or control PLA for LH2 and CD31 in NHDFs, treated with FKBP65 PPIase inhibitor tacrolimus or DMSO control combined with or without TGFβ1 treatment for 24 h (A), or transfected with esiRNA against FKBP10 or controls (RLUC and PLOD2), followed by TGFβ1 treatment for 2 d (B). Arrows indicate examples of PLA signals from LH2 and procollagen Iα1. (Scale bars: 50 µm.)